- May 06, 2026
CBT After Esketamine Can Prevent Relapses in Patients with Major Depression, Suicidal Ideation
- May 06, 2026Source: JAMA Psychiatry
Adjunctive Antipsychotics in Major Depressive Disorder
- May 06, 2026Source: JAMA Psychiatry
Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode
- April 21, 2026Source: Neuropsychopharmacology
Trajectories of Late-Life Depression: Insights From Molecular Imaging
- April 07, 2026
Yale Child, Adolescent, and Adult Psychiatry Program Announces Matched Residents
- March 09, 2026Source: NBC Connecticut (with Dr. Robert Ostroff)
Feeling SAD? How To Beat the Winter Blues
Yale Depression Research Program
Operated jointly by the Yale University School of Medicine Department of Psychiatry and Connecticut Mental Health Center, the Yale Depression Research Program has, for over 30 years, been committed to advancing the treatment of depression. By engaging in studies that seek to elucidate the underlying neurobiology of depression, we are striving to improve our ability to diagnose and treat mood disorders.
Executive Director, Gerard Sanacora, MD, PhD
Depression remains one of the most common and debilitating medical problems throughout the world. At the Yale Depression Research Program, we are committed to advancing our ability to understand, diagnose, and treat depression through innovative research.